Reply to Letter 'Morning dosing for dolutegravir-related insomnia and sleep disorders' by Capetti et al

C Hoffmann^{1

2}, T Welz³, M Sabranski¹, M Kolb^{3

4}, E Wolf⁵, H-J Stellbrink¹, C Wyen^{3

4}

Affiliations

¹ ICH Study Center Hamburg, Hamburg, Germany.
² Department of Medicine II, University of Schleswig-Holstein, Kiel, Germany.
³ Praxis am Ebertplatz, Cologne, Germany.
⁴ Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
⁵ MUC Research GmbH, Munich, Germany.

Free article

Comment

C Hoffmann et al. HIV Med. 2018 May.

Free article

. 2018 May;19(5):e60-e61.

doi: 10.1111/hiv.12539. Epub 2017 Aug 29.

C Hoffmann^{1

2}, T Welz³, M Sabranski¹, M Kolb^{3

4}, E Wolf⁵, H-J Stellbrink¹, C Wyen^{3

4}

¹ ICH Study Center Hamburg, Hamburg, Germany.
² Department of Medicine II, University of Schleswig-Holstein, Kiel, Germany.
³ Praxis am Ebertplatz, Cologne, Germany.
⁴ Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
⁵ MUC Research GmbH, Munich, Germany.

No abstract available

Comment on

Morning dosing for dolutegravir-related insomnia and sleep disorders.
Capetti AF, Di Giambenedetto S, Latini A, Sterrantino G, De Benedetto I, Cossu MV, Gori A. Capetti AF, et al. HIV Med. 2018 May;19(5):e62-e63. doi: 10.1111/hiv.12540. Epub 2017 Aug 1. HIV Med. 2018. PMID: 28762661 No abstract available.